AstraZeneca rises after its hypertension drug meets all late-stage trial endpoints

** Shares of Anglo-Swedish drug maker AstraZeneca AZN rose as much as 2% at 10,664 pence, among top gainers on FTSE 100 index

** Co says its drug Baxdrostat met all main and secondary goals of a late-stage study in patients with uncontrolled or treatment resistant hypertension

** Including session gains, AZN up ~0.5%, YTD